Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Oculus device receives FDA premarket approval
The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).
Lynwood, WA-The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus). The device will be launched at the annual meeting of the American Academy of Ophthalmology in Atlanta.
The instrument is designed to photograph the eye and obtain a Scheimpflug image of the cornea to evaluate its thickness. The implanted ophthalmic refractometer measures the refractive power of the eye.
Related Videos
Related Content
